证券代码：002901 证券简称：大博医疗 大博医疗科技股份有限公司 独立董事提名人声明 提名人大博医疗科技股份有限公司董事会现就提名肖伟为大博 医疗科技股份有限公司第四届董事会独立董事候选人发表公开声明。 被提名人已书面同意作为大博医疗科技股份有限公司第四届董事会 独立董事候选人（参见该独立董事候选人声明）。本次提名是在充 分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况后作出的，本提名人认为被提名人 符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易 所业务规则对独立董事候选人任职资格及独立性的要求，具体声明 并承诺如下事项： 一、被提名人已经通过大博医疗科技股份有限公司第三届董事会 提名委员会或者独立董事专门会议资格审查，提名人与被提名人不存 在利害关系或者其他可能影响独立履职情形的密切关系。 ☑ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百七十八条 等规定不得担任公司董事的情形。 ☑ 是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和 深圳证券交易所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 四、被提名人符合 ...

证券代码：002901 证券简称：大博医疗 大博医疗科技股份有限公司 独立董事提名人声明 提名人大博医疗科技股份有限公司董事会现就提名魏志华为大 博医疗科技股份有限公司第四届董事会独立董事候选人发表公开声 明。被提名人已书面同意作为大博医疗科技股份有限公司第四届董 事会独立董事候选人（参见该独立董事候选人声明）。本次提名是 在充分了解被提名人职业、学历、职称、详细的工作经历、全部兼 职、有无重大失信等不良记录等情况后作出的，本提名人认为被提 名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券 交易所业务规则对独立董事候选人任职资格及独立性的要求，具体 声明并承诺如下事项： 一、被提名人已经通过大博医疗科技股份有限公司第三届董事会 提名委员会或者独立董事专门会议资格审查，提名人与被提名人不存 在利害关系或者其他可能影响独立履职情形的密切关系。 ☑ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百七十八条 等规定不得担任公司董事的情形。 ☑ 是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和 深圳证券交易所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 四、被提名人符 ...

证券代码：002901 证券简称：大博医疗 公告编号：2026-005 大博医疗科技股份有限公司 关于召开 2026 年第一次临时股东会的通知 （1）现场会议时间：2026 年 2 月 2 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 2 月 2 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为 2026 年 2 月 2 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 1 月 28 日 7、出席对象： 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关 ...

证券代码：002901 证券简称：大博医疗 公告编号：2026-003 大博医疗科技股份有限公司 第三届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）第三届董事会第二十一次 会议于 2026 年 1 月 16 日在公司会议室以现场及通讯相结合方式召开，会议通知 以专人送达、传真、电子邮件、电话相结合的方式已于 2026 年 1 月 6 日向各位 董事发出，本次会议应参加董事 7 名，实际参加董事 7 名，本次会议的召开符合 《公司法》《公司章程》等法律法规的规定，合法有效。 本次会议由董事长林志雄先生主持，与会董事就会议议案进行了审议、表决， 形成了如下决议： 一、会议以 7 票同意、0 票反对、0 票弃权的表决结果审议通过了《关于选 举第四届董事会独立董事的议案》。 鉴于公司第三届董事会任期已届满，根据《公司法》《上市公司独立董事管 理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》及《公司章程》等相关规定，公司董事会提名委员会对新一届独立董事候 选人 ...

Group 1 - The company announced that its wholly-owned subsidiary, World, intends to acquire a 45.08% stake in Baimaisi (Xiamen) from related party He Xizhong for 3.7645 million yuan, which constitutes a related party transaction but does not qualify as a major asset restructuring [1] - The acquisition has been approved by the company's 21st meeting of the third board of directors, with three related directors abstaining from the vote [1] - Baimaisi (Xiamen) specializes in the sales and promotion of medical consumables, reporting revenue of 8.6912 million yuan and a net profit of 439,700 yuan for the year ending September 2025 [1] Group 2 - From the beginning of 2025 until the announcement date, the company has engaged in related party transactions totaling 12.2015 million yuan with the related party [1]

Core Insights - The biopharmaceutical industry in China is a strategic emerging industry, crucial for public health, technological innovation, and enhancing national pharmaceutical autonomy. The market size is projected to grow from CNY 4,210 billion in 2022 to CNY 8,000 billion by 2028, with an annual growth rate stabilizing between 10%-12% [1][2][23]. Industry Overview - In 2020, the biopharmaceutical market in China was valued at CNY 3,457 billion, increasing to CNY 4,100 billion in 2021, representing an 18.6% year-on-year growth. However, growth slowed to 2.68% in 2022, with a slight increase to CNY 4,210 billion [1][2]. - The industry is segmented into upstream (raw materials and medical devices), midstream (drug synthesis and production), and downstream (drug distribution). Biopharmaceuticals and chemical drugs have higher profit margins, with biopharmaceutical companies reporting gross margins of 80%-86% [2][4]. Xiamen Biopharmaceutical Industry - Xiamen is a key hub for biopharmaceutical industry development, recognized as a national strategic emerging industry cluster. The local government has implemented various supportive policies since 2016, focusing on innovation and industrialization [6][9]. - The industrial output value of Xiamen's biopharmaceutical sector reached CNY 1,045.87 billion in 2022, with a slight decline to CNY 847 billion in 2023, and is projected to stabilize around CNY 840 billion in 2024 [17][18]. Policy Environment - Xiamen's government has introduced multiple measures to support the biopharmaceutical industry, including financial incentives for R&D and commercialization, with significant rewards for new drug development and medical device innovation [9][26]. - The city aims to establish a CNY 100 billion venture capital fund and enhance the entire process from R&D to clinical application by 2025 [23][26]. Future Outlook - By 2025, Xiamen plans to significantly increase the number of registered biopharmaceutical companies, with projections indicating over 2,200 registered firms, marking a notable rise from previous years [18]. - The city aims to develop a CNY 700 billion biopharmaceutical industry chain, supported by specialized parks and a focus on various sub-sectors, including biopharmaceuticals and medical devices [23][26].

（文章来源：每日经济新闻） 每经AI快讯，1月9日，Wind数据显示，A股市场共计113只个股涨停。其中，机器人板块锋龙股份收获 11连板；商业航天板块多股连板，银河电子5连板、江顺科技4连板。 ...

Core Viewpoint - Dabo Medical (002901) reported a decline in stock price and mixed capital flow data, indicating potential investor caution despite strong financial performance in recent quarters [1][2]. Financial Performance - For the first three quarters of 2025, Dabo Medical achieved a main operating revenue of 1.876 billion yuan, a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a significant year-on-year growth of 77.03% [2]. - The non-recurring net profit was 346 million yuan, up 63.99% year-on-year [2]. - In Q3 2025 alone, the company reported a main operating revenue of 666 million yuan, a 17.82% increase compared to the same quarter last year [2]. - The net profit for Q3 2025 was 180 million yuan, showing a year-on-year increase of 77.49% [2]. - The non-recurring net profit for Q3 2025 was 123 million yuan, up 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with an investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Capital Flow - On January 7, 2026, Dabo Medical's stock closed at 49.48 yuan, down 1.61%, with a turnover rate of 0.68% and a trading volume of 19,500 hands, resulting in a transaction amount of 97.09 million yuan [1]. - The capital flow data for January 7 indicates a net outflow of 10.69 million yuan from main funds, accounting for 11.02% of the total transaction amount [1]. - Retail investors contributed a net inflow of 8.29 million yuan, representing 8.54% of the total transaction amount [1].

Core Viewpoint - Dabo Medical (002901) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the medical high-value consumables sector [2]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, an increase of 22.69% year-on-year [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a 77.03% increase year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 346 million yuan, up 63.99% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 666 million yuan, a 17.82% increase year-on-year [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, marking a 77.49% increase year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 123 million yuan, up 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Market Activity - As of January 5, 2026, Dabo Medical's stock closed at 49.63 yuan, up 4.77%, with a turnover rate of 1.07% and a trading volume of 30,900 hands, amounting to a transaction value of 152 million yuan [1]. - On January 5, the net outflow of main funds was 15.42 million yuan, accounting for 10.17% of the total transaction value, while retail investors saw a net inflow of 26.27 million yuan, representing 17.32% of the total transaction value [1].

Group 1 - The A-share market saw a significant decline in commercial aerospace stocks in the afternoon session [1] - Tianli Composite dropped over 11%, while Shenjian Co. approached the daily limit down [1] - Other notable declines included Superjet Co. down over 9%, Aerospace Hanyu down over 8%, and several companies including Paker New Materials and Goldwind Technology down over 7% [1] Group 2 - Companies such as Chuangyuan Technology, Zhaobiao Co., Jiangshun Technology, and others experienced declines exceeding 6% [1]